|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/127 | |
| C12N 15/88 | |||
| C12N 15/113 | |||
| A61K 48/00 |
| (11) | Number of the document | 2994167 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14795153.7 |
| Date of filing the European patent application | 2014-05-06 | |
| (97) | Date of publication of the European application | 2016-03-16 |
| (45) | Date of publication and mention of the grant of the patent | 2020-05-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/036915 |
| Date | 2014-05-06 |
| (87) | Number | WO 2014/182661 |
| Date | 2014-11-13 |
| (30) | Number | Date | Country code |
| 201361820036 P | 2013-05-06 | US |
| (72) |
KASPERKOVITZ, Pia, US
GOLLOB, Jared, US
|
| (73) |
Alnylam Pharmaceuticals, Inc.,
300 Third Street, 3rd Floor, Cambridge, MA 02142,
US
|
| (54) | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES |
| DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES |